Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

(NasdaqGM:CNTB), – Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

(NasdaqGM:BCAX), Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

(NASDAQ:KYTX), Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase

New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal

— Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full spectrum of drug biology — — Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 lossâ€'ofâ€'function cancers; expect to initiate Phase 1b/2a clinical trial

Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

(NASDAQ:RKDA), DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.(R) (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January

Geron Corporation Provides 2026 Financial Guidance

(NASDAQ:GERN), 2026 RYTELO(R) (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Geron Corporation

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

(NASDAQ:COGT), New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 years Clinical data presentations from all three pivotal trials, PEAK,

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

(NASDAQ:INAB), Repeat-doses of DeltEx(TM) Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocol Median overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several

Scroll to Top